{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:47:34Z","timestamp":1778201254895,"version":"3.51.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Breast cancer (BC) is the most common malignancy in women worldwide, with approximately two-thirds having hormone receptor-positive (HR+) tumors. New endocrine therapy (ET) strategies include combining ET agents as well as adding inhibitors targeting growth factors, angiogenesis, the mechanistic target of rapamycin, phosphoinositide 3-kinase (PI3K), or cyclin-dependent kinase 4\/6 to ET. Level 1 evidence supports use of fulvestrant plus anastrozole or palbociclib plus letrozole as first-line therapy for HR+\/HER\u2212 advanced BC with special consideration for the former in ET-na\u00efve patients, as well as everolimus plus exemestane or palbociclib plus fulvestrant as second-line therapy with special consideration in select first-line patients. Although the safety profiles of these combinations are generally predictable and manageable, both everolimus and palbociclib are associated with an increased risk of potentially serious or early-onset toxicities requiring individualized a priori adverse event risk stratification, earlier and more rigorous agent-specific monitoring, and patient education. Although each of these combinations improves progression-free survival, none with the exception of anastrazole plus fulvestrant have demonstrated improved overall survival. PI3K catalytic-\u03b1 mutations assessed from circulating tumor DNA represent the first potentially viable serum biomarker for the selection of ET combinations, and new data demonstrate the feasibility of this minimally invasive technique as an alternative to traditional tissue analysis. Therapeutic ratios of select ET combinations support their use in first- and second-line settings, but optimal sequencing has yet to be determined.<\/jats:p>","DOI":"10.1634\/theoncologist.2016-0185","type":"journal-article","created":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T03:00:37Z","timestamp":1479524437000},"page":"12-24","source":"Crossref","is-referenced-by-count":14,"title":["Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+\/HER2\u2013 Advanced Breast Cancer"],"prefix":"10.1093","volume":"22","author":[{"given":"Kathleen I.","family":"Pritchard","sequence":"first","affiliation":[{"name":"Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K.","family":"Chia","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Simmons","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"McLeod","sequence":"additional","affiliation":[{"name":"Kaleidoscope Strategic, Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Paterson","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre and University of Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Provencher","sequence":"additional","affiliation":[{"name":"Desch\u00eanes-Fabia Center for Breast Disease, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rayson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Dalhousie University, and Atlantic Clinical Cancer Research Unit, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"2021122417221510600_onco12062-bib-0001","volume-title":"Global Cancer Facts & Figures","author":"American Cancer Society","year":"2015","edition":"3rd"},{"key":"2021122417221510600_onco12062-bib-0002","volume-title":"GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012","author":"International Agency for Research on Cancer (IARC)","year":"2016"},{"key":"2021122417221510600_onco12062-bib-0003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3747\/co.20.1316","article-title":"Endocrine therapy for postmenopausal women with hormone receptor-positive HER-2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A Canadian consensus statement","volume":"20","author":"Pritchard","year":"2013","journal-title":"Curr Oncol"},{"key":"2021122417221510600_onco12062-bib-0004","volume-title":"Breast Cancer Facts & Figures 2015\u20132016","author":"American Cancer Society","year":"2015"},{"key":"2021122417221510600_onco12062-bib-0005","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0006","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"23","author":"Cardoso","year":"2014","journal-title":"Breast"},{"key":"2021122417221510600_onco12062-bib-0008","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mdr593","article-title":"The sequential use of endocrine treatment for advanced breast cancer: Where are we?","volume":"23","author":"Barrios","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0009","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ctrv.2013.03.004","article-title":"Fulvestrant for advanced breast cancer: A metaanalysis","volume":"39","author":"Al-Mubarak","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2021122417221510600_onco12062-bib-0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.critrevonc.2015.01.001","article-title":"Recent advances in the treatment of hormone receptor positive HER-2 negative metastatic breast cancer","volume":"94","author":"Fedele","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122417221510600_onco12062-bib-0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"key":"2021122417221510600_onco12062-bib-0012","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0013","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","article-title":"FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0014","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122417221510600_onco12062-bib-0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin- dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER-2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): A randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122417221510600_onco12062-bib-0016","first-page":"507","article-title":"PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+\/HER-2- advanced breast cancer (ABC)","volume":"34","author":"Finn","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"2021122417221510600_onco12062-bib-0017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0018","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2014.57.2388","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: The letrozole\/fulvestrant and avastin (LEA) study","volume":"33","author":"Mart\u00edn","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0019","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2015.66.1595","article-title":"Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (alliance)","volume":"34","author":"Dickler","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","article-title":"Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptorpositive locally advanced or metastatic breast cancer (SoFEA): A composite, multicentre, phase 3 randomised trial","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122417221510600_onco12062-bib-0021","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122417221510600_onco12062-bib-0022","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor positive, human epidermal growth factor receptor- 2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0023","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"2021122417221510600_onco12062-bib-0024","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clbc.2013.08.011","article-title":"Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER-2-negative, hormone receptor-positive breast cancer in BOLERO-2","volume":"13","author":"Pritchard","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"2021122417221510600_onco12062-bib-0025","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ejca.2013.04.011","article-title":"Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study","volume":"49","author":"Campone","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122417221510600_onco12062-bib-0026","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-013-2814-5","article-title":"Everolimus plus exemestane as first-line therapy in HR+, HER-2- advanced breast cancer in BOLERO-2","volume":"143","author":"Beck","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2021122417221510600_onco12062-bib-0027","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1185\/03007995.2013.836078","article-title":"Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER-2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy","volume":"29","author":"Campone","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2021122417221510600_onco12062-bib-0028","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","article-title":"Health- related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial","volume":"119","author":"Burris","year":"2013","journal-title":"Cancer"},{"key":"2021122417221510600_onco12062-bib-0029","volume-title":"PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+\/HER-2- advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial","author":"Baselga"},{"key":"2021122417221510600_onco12062-bib-0030","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.2014.56.7941","article-title":"Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: A randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (alliance)","volume":"32","author":"Burstein","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0031","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER-2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA- 3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122417221510600_onco12062-bib-0032","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER-2-negative metastatic breast cancer: Patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0033","doi-asserted-by":"crossref","first-page":"djt337","DOI":"10.1093\/jnci\/djt337","article-title":"Final overall survival: Fulvestrant 500\u2009mg vs 250\u2009mg in the randomized CONFIRM trial","volume":"106","author":"Leo","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021122417221510600_onco12062-bib-0034","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.breast.2014.01.016","article-title":"The therapeutic role of fulvestrant in the management of patients with hormone receptor positive breast cancer","volume":"23","author":"Ciruelos","year":"2014","journal-title":"Breast"},{"key":"2021122417221510600_onco12062-bib-0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/annonc\/mdj044","article-title":"Patients\u2019 preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer","volume":"17","author":"Fallowfield","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0036","first-page":"525","article-title":"Prevention of everolimus\/exemestane (EVE\/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial","volume":"34","author":"Rugo","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"2021122417221510600_onco12062-bib-0037","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdu009","article-title":"Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2","volume":"25","author":"Rugo","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0038","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neo.2015.01.005","article-title":"Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2","volume":"17","author":"Hortobagyi","year":"2015","journal-title":"Neoplasia"},{"issue":"suppl 4","key":"2021122417221510600_onco12062-bib-0039","first-page":"iv116","article-title":"Clinical patterns of palbociclib associated neutropenia in the PALOMA-1\/TRIO-18trial","volume":"25","author":"Finn","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0040","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021122417221510600_onco12062-bib-0041","first-page":"582","article-title":"Cyclin D1 as a biomarker of response to fulvestrant (F) in hormone receptor-positive (HR+) breast cancer (BC)","volume":"33","author":"Cascetta","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"2021122417221510600_onco12062-bib-0042","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/annonc\/mdv117.22","article-title":"AP-2gamma as a novel biomarker of endocrine resistance: Results from the TransCONFIRM study","volume":"26","author":"Malorni","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0043","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0044","volume-title":"Correlation of molecular alterations with efficacy of everolimus in hormone receptor\u2013positive, HER-2-negative advanced breast cancer: Results from BOLERO-2","author":"Hortobagyi","year":"2013"},{"key":"2021122417221510600_onco12062-bib-0045","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1158\/1078-0432.CCR-13-1551","article-title":"Molecular pathways: CDK4 inhibitors for cancer therapy","volume":"20","author":"Dickson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122417221510600_onco12062-bib-0046","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e395","article-title":"Targeting the PI3K\/AKT\/mTOR pathway: Biomarkers of success and tribulation","author":"Owonikoko","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2021122417221510600_onco12062-bib-0047","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","article-title":"Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from BOLERO-2","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122417221510600_onco12062-bib-0048","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021122417221510600_onco12062-bib-0049","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-11-2696","article-title":"Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood","volume":"18","author":"Higgins","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122417221510600_onco12062-bib-0050","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/annonc\/mdu288","article-title":"Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer","volume":"25","author":"Roth\u00e9","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122417221510600_onco12062-bib-0051","volume-title":"Results of the 3rd interim analysis of the non-interventional trial BRAWO\u2014Subanalysis of patients &lt;70 years and \u226570 years","author":"Tesch","year":"2015"},{"key":"2021122417221510600_onco12062-bib-0052","volume-title":"Treatment of Canadian postmenopausal women with ER\u2009+\u2009advanced breast cancer in the real-world setting with hormone therapy\u2009\u00b1\u2009targeted therapy (treat ER\u2009+\u2009ight)","author":"Novartis Pharmaceuticals","year":"2016"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/1\/12\/41913425\/oncolo_22_1_12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/1\/12\/41913425\/oncolo_22_1_12.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T17:23:01Z","timestamp":1640366581000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/1\/12\/6437678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,17]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0185","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1,1]]},"published":{"date-parts":[[2017,1,1]]}}}